| Identification | Back Directory | [Name]
8-BROMOADENOSINE-3',5'-CYCLIC MONOPHOSPHOROTHIOATE, RP-ISOMER SODIUM SALT | [CAS]
129735-00-8 | [Synonyms]
RP-8-BR-CAMPS
RP-8-BR-CAMPS, NA
8-BR-CAMPS NA, RP-ISOMER
RP-8-BR-CAMPS SODIUM SALT
8-BROMOADENOSINE-3',5'-CYCLIC * MONOPHOSPHOROTHIOAT
8-Bromoadenosine-3'',5''-cyclic monophosphothioate Rp isomer
8-BROMOADENOSINE 3',5'-CYCLIC MONOPHOSPHOTHIOATE, RP-ISOMER SODIUM SALT
8-BROMOADENOSINE-3',5'-CYCLIC MONOPHOSPHOROTHIOATE SODIUM SALT, RPISOMER
8-BROMOADENOSINE-3',5'-CYCLIC MONOPHOSPHOROTHIOATE, RP-ISOMER SODIUM SALT
ADENOSINE 3',5'-CYCLIC MONOPHOSPHOROTHIOATE, 8-BROMO-, RP-ISOMER, SODIUM SALT
8-bromoadenosine-3’,5’-cyclicmonophosphorothioate,rp-isomer(rp-8-br-camps),sodiumsalt | [Molecular Formula]
C10H10BrN5NaO5PS | [MDL Number]
MFCD04037241 | [MOL File]
129735-00-8.mol | [Molecular Weight]
446.15 |
| Chemical Properties | Back Directory | [Boiling point ]
690.3±65.0 °C(Predicted) | [density ]
2.70±0.1 g/cm3(Predicted) | [storage temp. ]
−20°C | [form ]
solid | [pka]
-0.60±0.60(Predicted) | [Water Solubility ]
water: 40mg/mL |
| Hazard Information | Back Directory | [Uses]
Rp-8-Br-cAMPS is an analog of cAMP and an inhibitor of PKA. Rp-8-Br-cAMPS occupies cAMP binding sites on PKA type I regulatory subunits, thereby preventing PKA dissociation and activation. Rp-8-Br-cAMPS can be used in the study of tumors and retrovirus-induced immune deficiency. Rp-8-Br-cAMPS also inhibits insulin secretion[1][2][3]. | [Biological Activity]
Cell permeable: yes''Primary Target
PKA 1''Product does not compete with ATP.''Reversible: yes | [in vivo]
Rp-8-Br-cAMPS (1 mg; intraperitoneal injection; 10 days) improves immune function in a mouse retrovirus infection model[3]. | Animal Model: | Murine leukemia retrovirus RadLV-Rs treated male C57BL/6 mice[3] | | Dosage: | 1 mg | | Administration: | Intraperitoneal injection (i.p.); 10 days | | Result: | Had no significant effect on the extent of lymphadenopathy and splenomegaly which is typical of RadLV-Rs retroviral infection.
Strongly increased responses to the anti-CD3 mAb.
Improved T cell responses.
|
| [References]
[1] Raskovalova T, et al. Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-activated NK cells: involvement of protein kinase A isozyme I (PKA I). Immunol Res. 2006;36(1-3):91-9. DOI:10.1385/IR:36:1:91
[2] Yang S, et al. Enhanced cAMP protein kinase A signaling determines improved insulin secretion in a clonal insulin-producing beta-cell line (INS-1 832/13). Mol Endocrinol. 2004 Sep;18(9):2312-20. DOI:10.1210/me.2004-0148
[3] Nayjib B, et al. In vivo administration of a PKA type I inhibitor (Rp-8-Br-cAMPS) restores T-cell responses in retrovirus-infected mice[J]. The Open Immunology Journal, 2008, 1(1). |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList1701258/0_EN.htm |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
Carbosynth
|
| Tel: |
+86 512 6260 5585 |
| Website: |
www.carbosynth.com |
| Company Name: |
SIGMA-RBI
|
| Tel: |
800 736 3690 (Orders) |
| Website: |
www.sigma-aldrich.com |
| Company Name: |
Alexis Corporation
|
| Tel: |
+41 61 926 8989 |
| Website: |
www.alexis-biochemicals.com |
|